UroGen Pharma Ltd.

Item5. Other Information.

Trading Plans

On* August 15, 2025,our Chief Medical Officer, Mark Schoenberg, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule10b5*-1(c) under the Exchange Act, to sell up to 40,000 ordinary shares. The trading plan expires on* November 18, 2026.*

Agenus License Agreement Termination

In* November 2025,we provided notice to terminate the license agreement with Agenus in connection with our decision to discontinue development of UGN-301. Under the terms of the license agreement, following notice of termination, the agreement will terminate upon the later of (a) the expiration of a180*-day notice period; or (b) completion of all wind-down activities and delivery of all Agenus Improvements (as defined in the license agreement) to Agenus. We donot expect to incur any costs in connection with the termination of the agreement.

Lease Extension

On* August 8, 2025,we entered into an amendment to our lease agreement, dated November 4, 2019,between us and Witman Properties, L.L.C. and Alexander Road at Davanne, L.L.C. (collectively, the “Landlord”). Pursuant to the amendment, we extended the expiration date of the lease from January 31, 2026to April 30, 2031.Commencing with the extension term on February 1, 2026,our base rent will be approximately$0.6* million per year, or approximately*$3.0* million in total during the extension term.

The foregoing summary of the lease amendment is qualified in its entirety by reference to the lease amendment, a copy of which is filed as Exhibit10.1 to this Quarterly Report.